{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-050390","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.919359+00:00","generated_at":"2026-05-25T00:48:49.465918+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"confidence":"high","headline":"Plus Therapeutics regains Nasdaq minimum equity compliance after private placement","bullets":["Received Nasdaq letter dated March 7, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).","Compliance achieved via private placement disclosed on March 4, 2025; escrow funds now released to the company.","Subject to Mandatory Panel Monitor until March 7, 2026; any future non-compliance triggers immediate delisting without cure period."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-050390","json":"https://secwatch.observer/filing/0001193125-25-050390.json","markdown":"https://secwatch.observer/filing/0001193125-25-050390.md","text":"https://secwatch.observer/filing/0001193125-25-050390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525050390/0001193125-25-050390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525050390/d938890d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:48:49.465918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}